^
Association details:
| Biomarker: | PIK3CA V955G |
|---|---|
| Cancer: | Colorectal Adenocarcinoma |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer
Excerpt:
Cell viability analysis suggested that in the presence of cetuximab in combination with 10 μmol/L 5-FU, compared with mock transfected cells, DiFi cells overexpressing p.K944N, p.V955G, p.V955I, p.K966E, p.E542K, p.E545K, and p.H1047R exhibited a high degree of resistance...These results demonstrate that these candidate mutations are likely to be involved in conferring resistance...
DOI:
10.1158/1078-0432.CCR-16-2738
